The role of human epididymis secretory protein E4 in patients with endometrial cancer and premalignant endometrial lesions. (2nd January 2017)

• Record Type: Journal Article
• Authors: Yılmaz, Setenay Arzu; Altınkaya, Sündüz Özlem; Kerimoglu, Özlem Seçilmiş; Tazegül Pekin, Aybike; Akyürek, Fikret; Ilhan, Tolgay Tuyan; Benzer, Nilgün; Unlu, Ali; Yuksel, Hasan; Celik, Cetin
• Is Part Of: Journal of obstetrics and gynaecology. Volume 37:Number 1(2017)
• Page Start: 58
• Page End: 63
• Publication Date: 2017-01-02
• Subjects: Endometrial cancer -- human epididymis secretory protein E4 -- endometrial hyperplasia -- atypical endometrial hyperplasia -- endometrial hyperplasia without atypia; Obstetrics -- Periodicals; Gynecology -- Periodicals; 618.05
• DOI: 10.3109/01443615.2016.1174199
• Languages: English
• ISSNs: 0144-3615

Abstract

Abstract: We evaluated the concentrations of human epididymis secretory protein E4 (HE4) and Ca-125 in relation to clinicopathologic features in patients with endometrial cancer and premalignant endometrial lesions. Women with abnormal uterine bleeding ( n = 167) who underwent endometrial sampling were divided into four groups. Group 1: endometrial cancer ( n = 68), group 2: atypical endometrial hyperplasia ( n = 12), group 3: endometrial hyperplasia without atypia ( n = 39) and group 4: controls ( n = 48). Women with endometrial cancer exhibited higher concentrations of HE4 levels than controls (91.4 pmol/L vs. 46.2 pmol/L, p < 0.001). HE4 levels were significantly higher in patients with lymphatic involvement, deep myometrial invasion, lymphovascular space involvement and non-endometrioid histology ( p < 0.001). The sensitivity, specificity, positive and negative predictive values for HE4 in detecting endometrial cancer were 72.7%, 84.4%, 80% and 78.4%, respectively. Preoperative HE4 levels are more elevated in women with endometrial cancer than those with benign endometrium as well as in women with prognostic high-risk factors with endometrial cancer. HE4 may be used as an additional marker in combination with other clinicopathologic features for planning the treatment.